Compare ALC & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALC | IQV |
|---|---|---|
| Founded | 1945 | 1982 |
| Country | Switzerland | United States |
| Employees | N/A | 93000 |
| Industry | Ophthalmic Goods | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.4B | 35.1B |
| IPO Year | 2002 | 2013 |
| Metric | ALC | IQV |
|---|---|---|
| Price | $67.20 | $206.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 16 |
| Target Price | $89.38 | ★ $227.13 |
| AVG Volume (30 Days) | ★ 2.1M | 1.4M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.25% | N/A |
| EPS Growth | N/A | ★ 4.67 |
| EPS | N/A | ★ 1.61 |
| Revenue | N/A | ★ $9,739,000,000.00 |
| Revenue This Year | $7.99 | $6.77 |
| Revenue Next Year | $6.38 | $5.89 |
| P/E Ratio | ★ $38.31 | $123.30 |
| Revenue Growth | N/A | ★ 41.60 |
| 52 Week Low | $61.84 | $154.50 |
| 52 Week High | $91.86 | $247.05 |
| Indicator | ALC | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 44.56 | 67.14 |
| Support Level | $65.99 | $159.91 |
| Resistance Level | $68.75 | $226.63 |
| Average True Range (ATR) | 1.24 | 5.07 |
| MACD | -0.13 | -0.58 |
| Stochastic Oscillator | 6.18 | 100.00 |
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.